<DOC>
	<DOC>NCT01235819</DOC>
	<brief_summary>To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.</brief_summary>
	<brief_title>Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Inclusion criteria T1DM &lt;3 months GAD Antibody+ Stimulated C peptide&lt;0.5ng/ml Ketosis at onset Age &lt; 30 yr Exclusion criteria Age &gt; 30 yr Pancreatic disease significant systemic complication</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>T1DM &lt;3 months GAD Antibody+ or Stimulated C peptide&lt;0.5 ng/ml Ketosis at onset Age &lt; 30 yr Age &gt; 30 yr Pancreas disease Significant systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>sitagliptin</keyword>
</DOC>